93. Braunschweig F, Linde C, Benson L, Ståhlberg M, Dahlström U, Lund LH. New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy. European journal of heart failure. Mar 2017;19(3):366-376. doi:10.1002/ejhf.563
94. Simpson J, Jhund PS, Lund LH, et al. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiol. Apr 1 2020;5(4):432-441. doi:10.1001/jamacardio.2019.5850
95. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. European heart journal. Jan 2006;27(1):65-75. doi:10.1093/eurheartj/ehi555
96. Sakata Y, Tsuji K, Nochioka K, Shimokawa H. Transition of Left Ventricular Ejection Fraction in Heart Failure. Adv Exp Med Biol. 2018;1067:5-15. doi:10.1007/5584_2018_178
97. Oremus M, Don-Wauchope A, McKelvie R, et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev. Aug 2014;19(4):471-505. doi:10.1007/s10741-014-9439-6
98. Santaguida PL, Don-Wauchope AC, Oremus M, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev. Aug 2014;19(4):453-70. doi:10.1007/s10741-014-9442-y
99. Aimo A, Januzzi JL, Jr., Vergaro G, et al. High-sensitivity troponin T, NT- proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International journal of cardiology. Feb 15 2019;277:166- 172. doi:10.1016/j.ijcard.2018.10.079
100. Aimo A, Januzzi JL, Jr., Vergaro G, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation. Jan 16 2018;137(3):286-297. doi:10.1161/circulationaha.117.031560
101. Maddox TM, Januzzi JL, Jr., Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. Feb 16 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022
Có thể bạn quan tâm!
-
Giá Trị Tiên Đoán Của Các Yếu Tố Lâm Sàng, Cận Lâm Sàng Và Sst2 Với Biến Cố Tử Vong Do Mọi Nguyên Nhân -
Phối Hợp Với Các Yếu Tố Lâm Sàng -
Vai trò tiên lượng của dấu ấn sinh học sST2 trong suy tim - 19 -
Vai trò tiên lượng của dấu ấn sinh học sST2 trong suy tim - 21 -
Thông Tin Về Nghiên Cứu Mục Đích Và Tiến Hành Nghiên Cứu -
Vai trò tiên lượng của dấu ấn sinh học sST2 trong suy tim - 23
Xem toàn bộ 193 trang tài liệu này.
102. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. Aug 8 2017;136(6):e137-e161. doi:10.1161/cir.0000000000000509
103. Taylor CJ, Moore J, O'Flynn N. Diagnosis and management of chronic heart failure: NICE guideline update 2018. Br J Gen Pract. May 2019;69(682):265-266. doi:10.3399/bjgp19X702665
104. Zhang J, Begley A, Jackson R, et al. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose- response meta-analysis. Clin Res Cardiol. Feb 2019;108(2):119-132. doi:10.1007/s00392-018-1302-7
105. Oliva F, Sormani P, Contri R, et al. Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. International journal of cardiology. Feb 15 2018;253:97-104. doi:10.1016/j.ijcard.2017.09.191
106. Nymo SH, Aukrust P, Kjekshus J, et al. Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. JACC Heart failure. Apr 2017;5(4):256-264. doi:10.1016/j.jchf.2017.01.008
107. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N- terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. Sep 28 2004;110(13):1780-6. doi:10.1161/01.Cir.0000143059.68996.A7
108. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). Journal of the American College of Cardiology. Sep 16 2008;52(12):997-1003. doi:10.1016/j.jacc.2008.04.069
109. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. Journal of the American College of Cardiology. Feb 18 2004;43(4):635-41. doi:10.1016/j.jacc.2003.09.044
110. Graham I, Shear C, De Graeff P, et al. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother. Apr 1 2018;4(2):119-127. doi:10.1093/ehjcvp/pvx031
111. Stolfo D, Stenner E, Merlo M, et al. Prognostic Impact of BNP Variations in Patients Admitted for Acute Decompensated Heart Failure with In-Hospital Worsening Renal Function. Heart Lung Circ. Mar 2017;26(3):226-234. doi:10.1016/j.hlc.2016.06.1205
112. Zile MR, Claggett BL, Prescott MF, et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. Journal of the American College of Cardiology. Dec 6 2016;68(22):2425-2436. doi:10.1016/j.jacc.2016.09.931
113. Pascual-Figal D, Wachter R, Senni M, et al. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection
Fraction: TRANSITION Study. JACC Heart failure. Oct 2020;8(10):822-833. doi:10.1016/j.jchf.2020.05.012
114. Noveanu M, Breidthardt T, Potocki M, et al. Direct comparison of serial B- type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure. Crit Care. 2011;15(1):R1. doi:10.1186/cc9398
115. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. May 3 2022;145(18):e895-e1032. doi:10.1161/cir.0000000000001063
116. Seronde MF, Gayat E, Logeart D, et al. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. International journal of cardiology. Oct 9 2013;168(4):3404-11. doi:10.1016/j.ijcard.2013.04.164
117. Lê Xuân Trường, Nguyễn Chí Thanh. Giá trị của xét nghiệm MR-PROANP trong tiên lượng tử vong dài hạn trên bệnh nhân suy tim cấp. Tạp chí Y Học Thành phố Hồ Chí Minh. 2019;23(3):284-288.
118. Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. European journal of heart failure. Apr 2010;12(4):338-47. doi:10.1093/eurjhf/hfp206
119. Arrigo M, Truong QA, Szymonifka J, et al. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. Europace. Nov 1 2017;19(11):1848-1854. doi:10.1093/europace/euw305
120. Maisel AS, Duran JM, Wettersten N. Natriuretic Peptides in Heart Failure: Atrial and B-type Natriuretic Peptides. Heart Fail Clin. Jan 2018;14(1):13-25. doi:10.1016/j.hfc.2017.08.002
121. Felker GM, Hasselblad V, Tang WH, et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. European journal of heart failure. Nov 2012;14(11):1257-64. doi:10.1093/eurjhf/hfs110
122. Gravning J, Askevold ET, Nymo SH, et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circ Heart Fail. Jan 2014;7(1):96-103. doi:10.1161/circheartfailure.113.000450
123. Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced
ejection fraction and anaemia: RED-HF study. European journal of heart failure. Feb 2018;20(2):268-277. doi:10.1002/ejhf.988
124. Rørth R, Jhund PS, Kristensen SL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European journal of heart failure. Jan 2019;21(1):40-49. doi:10.1002/ejhf.1359
125. Kaier TE, Twerenbold R, Puelacher C, et al. Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction. Circulation. Oct 17 2017;136(16):1495-1508. doi:10.1161/circulationaha.117.028084
126. Schulte C, Barwari T, Joshi A, et al. Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury. Circ Res. Jul 19 2019;125(3):328-340. doi:10.1161/circresaha.119.314937
127. El Amrousy D, Hodeib H, Suliman G, Hablas N, Salama ER, Esam A. Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure. Pediatr Cardiol. Feb 2017;38(2):418-424. doi:10.1007/s00246-016-1532-2
128. Piek A, Du W, de Boer RA, Silljé HHW. Novel heart failure biomarkers: why do we fail to exploit their potential? Crit Rev Clin Lab Sci. Jun 2018;55(4):246-263. doi:10.1080/10408363.2018.1460576
129. Ishii J, Ozaki Y, Lu J, et al. Prognostic value of serum concentration of heart- type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem. Aug 2005;51(8):1397-404. doi:10.1373/clinchem.2004.047662
130. Lê Xuân Trường, Lê Xuân Minh Phúc, Nguyễn Thanh Trầm, Nguyễn Minh Thanh, Trần Thành Vinh. Giá trị của protein gắn acid béo cơ tim (H-FABP) trong chẩn đoán sớm nhồi máu cơ tim cấp. Tạp chí Y Học Thành phố Hồ Chí Minh. 2019;23(2):91-98.
131. Kazimierczyk E, Kazimierczyk R, Harasim-Symbor E, et al. Persistently elevated plasma heart-type fatty acid binding protein concentration is related with poor outcome in acute decompensated heart failure patients. Clin Chim Acta. Dec 2018;487:48-53. doi:10.1016/j.cca.2018.09.004
132. Niizeki T, Takeishi Y, Arimoto T, et al. Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circulation journal : official journal of the Japanese Circulation Society. Aug 2005;69(8):922-7. doi:10.1253/circj.69.922
133. Hoffmann U, Espeter F, Weiß C, et al. Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic
insights compared to NT-proBNP and troponin I. BMC cardiovascular disorders. Jun 14 2015;15:50. doi:10.1186/s12872-015-0026-0
134. Kutsuzawa D, Arimoto T, Watanabe T, et al. Ongoing myocardial damage in patients with heart failure and preserved ejection fraction. J Cardiol. Dec 2012;60(6):454-61. doi:10.1016/j.jjcc.2012.06.006
135. Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. Nov 2009;409(1-2):96-9. doi:10.1016/j.cca.2009.09.001
136. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. Nov 9 2004;110(19):3121-8. doi:10.1161/01.Cir.0000147181.65298.4d
137. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin- 3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. May 2010;99(5):323-8. doi:10.1007/s00392- 010-0125-y
138. Đặng Quang Toàn, Tạ Thị Thanh Hương. Dấu ấn sinh học galectin-3 trong suy tim cấp. Tạp chí Y Học Thành phố Hồ Chí Minh. 2019;23(2):135-144.
139. Bùi Thị Thanh Hiền, Hoàng Anh Tiến, Đinh Hiếu Nhân. Kết quả bước đầu nghiên cứu nồng độ Galectin-3 ở bệnh nhân suy tim. Tạp chí Y Dược học. 2019;9(6+7):89.
140. Frank D, Kuhn C, Brors B, et al. Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension. Feb 2008;51(2):309-18. doi:10.1161/hypertensionaha.107.098046
141. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth- differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. Oct 5 2010;122(14):1387-95. doi:10.1161/circulationaha.109.928846
142. Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. Journal of the American College of Cardiology. Sep 11 2007;50(11):1054-60. doi:10.1016/j.jacc.2007.04.091
143. Tang WH, Wu Y, Grodin JL, et al. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC Heart failure. Jan 2016;4(1):68-77. doi:10.1016/j.jchf.2015.07.015
144. Skali H, Gerwien R, Meyer TE, Snider JV, Solomon SD, Stolen CM. Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly
Symptomatic Heart Failure: Results from MADIT-CRT. J Cardiovasc Transl Res. Dec 2016;9(5-6):421-428. doi:10.1007/s12265-016-9713-1
145. Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. May 2014;7(3):418-26. doi:10.1161/circheartfailure.113.001036
146. Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Journal of the American College of Cardiology. Jan 21 2014;63(2):158-66. doi:10.1016/j.jacc.2013.07.087
147. Spoletini I, Coats AJS, Senni M, Rosano GMC. Monitoring of biomarkers in heart failure. Eur Heart J Suppl. Dec 2019;21(Suppl M):M5-m8. doi:10.1093/eurheartj/suz215
148. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. Oct 2008;7(10):827-40. doi:10.1038/nrd2660
149. Tominaga S, Inazawa J, Tsuji S. Assignment of the human ST2 gene to chromosome 2 at q11.2. Hum Genet. May 1996;97(5):561-3. doi:10.1007/bf02281860
150. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. Nov 2016;16(11):676-689. doi:10.1038/nri.2016.95
151. Larsen KM, Minaya MK, Vaish V, Peđa MMO. The Role of IL-33/ST2 Pathway in Tumorigenesis. Int J Mol Sci. Sep 9
2018;19(9)doi:10.3390/ijms19092676
152. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. Dec 3 2002;106(23):2961-6. doi:10.1161/01.cir.0000038705.69871.d9
153. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2- associated cytokines. Immunity. Nov 2005;23(5):479-90. doi:10.1016/j.immuni.2005.09.015
154. Baba Y, Maeda K, Yashiro T, et al. GATA2 is a critical transactivator for the human IL1RL1/ST2 promoter in mast cells/basophils: opposing roles for GATA2 and GATA1 in human IL1RL1/ST2 gene expression. J Biol Chem. Sep 21
2012;287(39):32689-96. doi:10.1074/jbc.M112.374876
155. Tseng CCS, Huibers MMH, van Kuik J, de Weger RA, Vink A, de Jonge N. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium. J Cardiovasc Transl Res. Feb 2018;11(1):15-21. doi:10.1007/s12265-017-9775-8
156. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. Apr 2 2015;115(7 Suppl):3b-7b. doi:10.1016/j.amjcard.2015.01.034
157. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One. Oct 6 2008;3(10):e3331. doi:10.1371/journal.pone.0003331
158. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Küchler AM. Interleukin-
33 - cytokine of dual function or novel alarmin? Trends Immunol. May 2009;30(5):227-33. doi:10.1016/j.it.2009.03.003
159. Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. Oct 2008;9(10):1006-12. doi:10.1038/embor.2008.145
160. Zhang F, Tossberg JT, Spurlock CF, Yao SY, Aune TM, Sriram S. Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis. Ann Clin Transl Neurol. May 1 2014;1(5):307-318. doi:10.1002/acn3.47
161. Ali S, Mohs A, Thomas M, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol. Aug 15 2011;187(4):1609-16. doi:10.4049/jimmunol.1003080
162. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A. Jun 2 2009;106(22):9021-6. doi:10.1073/pnas.0812690106
163. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. Dec 2014;31:31-7. doi:10.1016/j.coi.2014.09.004
164. Lefrançais E, Duval A, Mirey E, et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A. Oct 28 2014;111(43):15502-7. doi:10.1073/pnas.1410700111
165. Lüthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. Jul 17 2009;31(1):84-98. doi:10.1016/j.immuni.2009.05.007
166. Hardman C, Ogg G. Interleukin-33, friend and foe in type-2 immune responses. Curr Opin Immunol. Oct 2016;42:16-24. doi:10.1016/j.coi.2016.05.004
167. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. Embo j. Mar 1 1994;13(5):1176-88.
168. Iwahana H, Yanagisawa K, Ito-Kosaka A, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2
gene in UT-7 and TM12 cells. Eur J Biochem. Sep 1999;264(2):397-406. doi:10.1046/j.1432-1327.1999.00615.x
169. Millar NL, O'Donnell C, McInnes IB, Brint E. Wounds that heal and wounds that don't - The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis. Semin Cell Dev Biol. Jan 2017;61:41-50. doi:10.1016/j.semcdb.2016.08.007
170. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. Aug 15 2007;179(4):2551-5. doi:10.4049/jimmunol.179.4.2551
171. Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. Nov 2012;60(2):514-21. doi:10.1016/j.cyto.2012.06.286
172. O'Donnell C, Mahmoud A, Keane J, et al. An antitumorigenic role for the IL-
33 receptor, ST2L, in colon cancer. Br J Cancer. Jan 12 2016;114(1):37-43. doi:10.1038/bjc.2015.433
173. Akimoto M, Takenaga K. Role of the IL-33/ST2L axis in colorectal cancer progression. Cell Immunol. Sep 2019;343:103740. doi:10.1016/j.cellimm.2017.12.014
174. Zhao J, Wei J, Mialki RK, et al. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat Immunol. Jun 3 2012;13(7):651-8. doi:10.1038/ni.2341
175. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun. Jun 27 1997;235(3):474-8. doi:10.1006/bbrc.1997.6810
176. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. Sep 7 2007;282(36):26369-80. doi:10.1074/jbc.M704916200
177. Cohen ES, Scott IC, Majithiya JB, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun. Sep 14 2015;6:8327. doi:10.1038/ncomms9327
178. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. Mar 2 1998;187(5):787- 94. doi:10.1084/jem.187.5.787
179. Pusceddu I, Dieplinger B, Mueller T. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans. Clin Chim Acta. Aug 2019;495:493-500. doi:10.1016/j.cca.2019.05.023
180. Bayés-Genís A, Núđez J, Lupón J. Soluble ST2 for Prognosis and Monitoring in Heart Failure: The New Gold Standard? Journal of the American